Cargando…
Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols
Variability in the subfertile patient population excludes the possibility of a single approach to controlled ovarian stimulation (COS) covering all the requirements of a patient. Modern technology has led to the development of new drugs, treatment options and quantitative methods that can identify s...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299595/ https://www.ncbi.nlm.nih.gov/pubmed/22309877 http://dx.doi.org/10.1186/1477-7827-10-9 |
_version_ | 1782226127825141760 |
---|---|
author | Alviggi, Carlo Humaidan, Peter Ezcurra, Diego |
author_facet | Alviggi, Carlo Humaidan, Peter Ezcurra, Diego |
author_sort | Alviggi, Carlo |
collection | PubMed |
description | Variability in the subfertile patient population excludes the possibility of a single approach to controlled ovarian stimulation (COS) covering all the requirements of a patient. Modern technology has led to the development of new drugs, treatment options and quantitative methods that can identify single patient characteristics. These could potentially be used to match patients with the right treatment options to optimise efficacy, safety and tolerability during COS. Currently, age and follicle-stimulating hormone (FSH) level remain the most commonly used single patient characteristics in clinical practice. These variables only provide a basic prognosis for success and indications for standard COS treatment based on gross patient categorisation. In contrast, the anti-Müllerian hormone level appears to be an accurate predictor of ovarian reserve and response to COS, and could be used successfully to guide COS. The antral follicle count is a functional biomarker that could be useful in determining the dose of FSH necessary during stimulation and the success of treatment. Finally, in the future, genetic screening may allow an individual patient's response to stimulation during COS to be predicted based on genotype. Unfortunately, despite the predictive power of these measures, no single biomarker can stand alone as a guide to determine the best treatment option. In the future, hormonal, functional and genetic biomarkers will be used together to personalise COS. |
format | Online Article Text |
id | pubmed-3299595 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-32995952012-03-13 Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols Alviggi, Carlo Humaidan, Peter Ezcurra, Diego Reprod Biol Endocrinol Review Variability in the subfertile patient population excludes the possibility of a single approach to controlled ovarian stimulation (COS) covering all the requirements of a patient. Modern technology has led to the development of new drugs, treatment options and quantitative methods that can identify single patient characteristics. These could potentially be used to match patients with the right treatment options to optimise efficacy, safety and tolerability during COS. Currently, age and follicle-stimulating hormone (FSH) level remain the most commonly used single patient characteristics in clinical practice. These variables only provide a basic prognosis for success and indications for standard COS treatment based on gross patient categorisation. In contrast, the anti-Müllerian hormone level appears to be an accurate predictor of ovarian reserve and response to COS, and could be used successfully to guide COS. The antral follicle count is a functional biomarker that could be useful in determining the dose of FSH necessary during stimulation and the success of treatment. Finally, in the future, genetic screening may allow an individual patient's response to stimulation during COS to be predicted based on genotype. Unfortunately, despite the predictive power of these measures, no single biomarker can stand alone as a guide to determine the best treatment option. In the future, hormonal, functional and genetic biomarkers will be used together to personalise COS. BioMed Central 2012-02-06 /pmc/articles/PMC3299595/ /pubmed/22309877 http://dx.doi.org/10.1186/1477-7827-10-9 Text en Copyright ©2012 Alviggi et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Alviggi, Carlo Humaidan, Peter Ezcurra, Diego Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols |
title | Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols |
title_full | Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols |
title_fullStr | Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols |
title_full_unstemmed | Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols |
title_short | Hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols |
title_sort | hormonal, functional and genetic biomarkers in controlled ovarian stimulation: tools for matching patients and protocols |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3299595/ https://www.ncbi.nlm.nih.gov/pubmed/22309877 http://dx.doi.org/10.1186/1477-7827-10-9 |
work_keys_str_mv | AT alviggicarlo hormonalfunctionalandgeneticbiomarkersincontrolledovarianstimulationtoolsformatchingpatientsandprotocols AT humaidanpeter hormonalfunctionalandgeneticbiomarkersincontrolledovarianstimulationtoolsformatchingpatientsandprotocols AT ezcurradiego hormonalfunctionalandgeneticbiomarkersincontrolledovarianstimulationtoolsformatchingpatientsandprotocols |